SCIENION is a global market leader in ultra-low volume precision dispensing and microarray as well as biosensor technologies.
SCIENION wants to improve and accelerate the development of innovative, reliable, cost-efficient diagnostic and bioanalysis test platforms for the sake of patients, consumers, public health and environmental protection all over the world. We support our customers in any way to achieve this goal and we strive to be the number one partner for all players with the same objective.
Products & Services
Quality management has always been key for us. SCIENION is certified according to ISO 9001:2015.
Strongly committed to R&D
SCIENION is strongly committed to R&D – with the aim to shape and accelerate the development of next generation diagnostic and bioanalysis test platforms. Beside internal research efforts, we take part in various national and international research projects to develop innovative products – together with academic and industrial partners.
Part of the BICO Group
Founded in 2016, BICO (formerly CELLINK) is the world’s leading bioconvergence company, organized into three business areas: Biosciences, Bioautomation, and Bioprinting. BICO reduces the organ shortage and speeds up drug development by providing accessible life science solutions that combine biology and technology, fundamentally shifting the global healthcare industry.
Using a combination of robotics, artificial intelligence, advanced genomics, and 3D bioprinting, our innovative technologies enable researchers and practitioners in the life sciences to conduct cell line development, perform high-throughput drug screening and diagnostics, and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. BICO is the future of life-saving treatments, as we enable our customers to improve people’s health and lives.
We have over 32,000 installed instruments in more than 3,500 laboratories, including the top 20 pharmaceutical companies. They are being used in more than 65 countries, and have been cited in more than 11,000 publications. BICO is listed on Nasdaq Stockholm under BICO.